Bryan Kay
CVRx initiates BENEFIT-HF trial of Barostim device in “significantly expanded population”
CVRx recently announced the start of the BENEFIT-HF clinical trial, a randomised study designed to evaluate the impact of the Barostim neuromodulation device in...